Re-store Biomedicine Group

Re-store Biomedicine Group (瑞思德), formally Qingdao Re-store Biotechnology Co., Ltd. (青岛瑞思德生物科技有限公司), is a Chinese high-technology biomedical company headquartered in Qingdao, Shandong. According to its official website, the group is built around genomics, cell biology, microbiome science, medical artificial intelligence and biomedical big data, and describes itself as a service platform for preventive medicine and personalized healthcare with the mission of "realizing individual-centered precision intelligent medicine." Its stated business scope covers third-party medical testing (cell functional medical testing and genetic testing), adult stem cell and immune cell storage, and new cell drug research and development. The group operates through several subsidiaries and business units: the Re-store Medical Testing Laboratory (瑞思德医学检验实验室), a third-party medical laboratory; Re-store Hospital (瑞思德医院); Zhongke Ruishen Biotechnology Research Institute (中科瑞参生物科技研究院); and Ruiran Information Technology Co., Ltd. (瑞然信息技术有限公司). It also runs an internet hospital platform and a life-science popular-science education base in Qingdao, approved in 2016, which provides life-science education for school students and health education for adults. Re-store presents itself as a platform combining a biomedical big-data center, a precision-medicine platform and a bioinformatics platform, with three technology pillars — gene technology, cell technology and microbiome technology — and applications spanning life-science education, life-science research, clinical testing and treatment, and biomedical information technology. The company states that it has applied for more than seventy patents, of which thirty have been granted, and holds six software copyright certificates and two work registration certificates. It reports honors including National High-Tech Enterprise status, ranking 13th in the 2018 Deloitte China Technology Fast 50, Shandong Gazelle Enterprise, Qingdao Specialized and Sophisticated Demonstration Enterprise, and Qingdao Enterprise Technology Center, as well as ISO 9001 quality management certification, national intellectual property management system certification and a AAA corporate credit rating from the Ministry of Commerce. The company's public communications emphasize large-scale testing data. It states that its medical testing and pathology diagnostics cover more than 2,700 items, with annual specimen volumes in the millions, a rare-disease sample bank and database containing nearly 70,000 positive cases covering more than 2,100 rare diseases, cumulative cervical lesion testing of more than 43.5 million cases from 31 provinces as of 2018, more than 1.1 million inherited metabolic disease mass-spectrometry tests between 2010 and 2016, and a 1.4 million-case 25-hydroxyvitamin D testing dataset. Recent news items include a 2025 public notice on a joint nomination with Qingdao University for a Qingdao Science and Technology Award for a project on iPSC-derived trabecular meshwork cells for glaucoma treatment, recognition as a Qingdao private-sector leading benchmark enterprise for two consecutive years, and approval to establish a Shandong postdoctoral innovation practice base.

Re-store Biomedicine Group, formally Qingdao Re-store Biotechnology Co., Ltd., is a Qingdao-based biomedical company. Its official website describes a group structured around a biomedical big-data center, a precision-medicine platform and a bioinformatics platform, supported by gene, cell and microbiome technologies. The group's stated mission is to realize individual-centered precision intelligent medicine, and its business spans third-party medical testing, adult stem cell and immune cell storage, and cell drug development. The company's history is documented mainly through its own disclosures and news items rather than a detailed public timeline. Its Qingdao life-science popular-science education base was approved in 2016, indicating an early commitment to science education alongside its clinical and laboratory work. The company reports that between 2010 and 2016 it cumulatively tested more than 1.1 million samples for inherited metabolic diseases using mass spectrometry, one of the earlier such programs in China. By 2018 its cervical lesion testing center had reportedly received 43.5 million cervical cancer screening specimens from 31 provinces, and in that year the company ranked 13th in the Deloitte China Technology Fast 50. Re-store has since expanded its platform through subsidiaries including the Re-store Medical Testing Laboratory, Re-store Hospital, Zhongke Ruishen Biotechnology Research Institute and Ruiran Information Technology Co., Ltd., and it operates an internet hospital. It reports more than 2,700 medical testing and pathology diagnostic items, a rare-disease sample bank with nearly 70,000 positive cases covering over 2,100 rare diseases, and a 1.4 million-case vitamin D testing dataset. The company states that it has applied for more than seventy patents, with thirty granted, and holds six software copyrights and two work registration certificates. It has received recognition as a National High-Tech Enterprise, Shandong Gazelle Enterprise, Qingdao Specialized and Sophisticated Demonstration Enterprise and Qingdao Enterprise Technology Center, and has obtained ISO 9001, national intellectual property management system and AAA credit certifications. In 2025 the company publicly noticed a joint nomination with Qingdao University for a Qingdao Science and Technology Award for a project on iPSC-derived trabecular meshwork cells for glaucoma treatment, reflecting ongoing research activity in cell-based therapies. It has also been recognized as a Qingdao private-sector leading benchmark enterprise for two consecutive years and approved to establish a Shandong postdoctoral innovation practice base. The group is led by chairman Chen Mengmeng.

• 2025

  Public notice of joint nomination with Qingdao University for 2025 Qingdao Science and Technology Award for iPSC-derived trabecular meshwork cell project for glaucoma.

• 2024

  Selected as a 2024 third-batch Qingdao science and technology innovation voucher service institution.

• 2018

  Ranked 13th in the Deloitte China Technology Fast 50; cervical lesion testing center reported 43.5 million cumulative specimens from 31 provinces.

• 2016

  Re-store Qingdao Life Science Popular Science Education Base approved.

• 2010

  Company reports beginning cumulative mass-spectrometry testing of inherited metabolic diseases, reaching over 1.1 million samples by 2016.

Preventive medicine and personalized healthcare platform focused on precision intelligent medicine, combining testing, cell technology and biomedical big data.

• Third-party medical testing

  Cell functional medical testing and genetic testing, with more than 2,700 testing and pathology diagnostic items.

• Adult stem cell and immune cell storage

  Storage services based on the company's cell preparation, storage and quality control technology system.

• Cell drug research and development

  Research and development of new cell-based drugs, including iPSC-derived cell therapy research.

• Internet hospital

  Online platform connecting doctors and patients for one-stop services.

1. 1瑞思德官网首页restorecn.com
2. 2瑞思德公司简介restorecn.com
3. 3关于青岛瑞思德生物科技有限公司推荐提名2025年度青岛市科学技术奖项目公示restorecn.com
4. 4关于开展寻找青岛市“最美巾帼科创人”系列活动的通知restorecn.com
5. 5Wikidata: Re-store Biomedicine Groupwikidata.org